This study was conducted to obtain acute information of the oral dose toxicity of DHU001, a polyherbal formula in male and female mice. In order to calculated 50% lethal dose (LD 5 0
INTRODUCTION
DHU001 is a mixed herbal formula consisted of 7 types of aqueous extracts; Ficis fructus, Liriopis tuber, Platycodi radix, Schisandrae fructus, Glycyrrhizae radix, Zingiberis rhizome and Menthae herba, and developed for respiratory disorders. Among 7 types of herbal components of DHU001, Liriopis tuber (Park and Geon, 2003) , Platycodi radix (Kim et al., 2004) , Schisandrae fructus (Narimanian et al., 2005; Rhyu et al., 2006) , Glycyrrhizae radix (Sun and Pan, 2006) , Zingiberis rhizome (Aimbire et al., 2007; Ghayur et al., 2008) and Menthae herba (Shin, 2003) have been used to treat various respiratory symptoms. In addition, anti-inflammatory effects on the acute inflammation of DHU001 itself, were also already reported (Back et al., 2008) . As increase of the concern in the functional food and well being in life, the demands and consumption of functional food originated from natural sources are increased (Lee et al., 2003) . However, the toxicological aspects about these natural origin-functional foods has been neglected because of the reasons that they have been used as various purpose for long times. Therefore, it is considered that more detail and systemic toxicological studies should be tested to control the abuse and potential toxicities even if they have been used as traditional folk medicine.
The objective of the present study was to obtain the primary safety information about DHU001, a polyherbal formula being developed for respiratory disorders, and further clarifies their safety for clinical use. In order to observe the 50% lethal dose (LD 50 ), approximate lethal dosage (ALD), test articles were once orally administered to female and male ICR mice at dose levels of 2000, 1000, 500, 250 and 0 (control) mg/kg (body weight) according to the recommendation of KFDA Guidelines (2005) . The mortality, changes on body weight, clinical signs and gross observation were monitored during 14 days after oral administration of DHU001. Organ weights and histopathology of 12 types of principle organs were also monitored.
MATERIALS AND METHODS
Experimental animals. Each of twenty-five female and male ICR mice (6-wk old upon receipt, SLC, Japan) was used after acclimatization for 8 days. Five animals were allocated per a polycarbonate cage in a temperature (202 5 o C) and humidity (40~45%) controlled room. Light : dark cycle was 12 h : 12 h and feed (Samyang, Korea) and water were supplied free to access. All animals were overnight fasted (about 18 h) before dosing and terminal necropsy.
Animals were marked by picric acid.
Preparation of DHU001. The herbal compositions of DHU001 were listed in Table 1 . Each herbal component was purchased from Cho-Heung Pharmaceutical Ind. Co. (Daegu, Korea) after confirmation of the morphology under microscopy. Approximated amounts of each herbal component was mixed (317.5 g) and boiled in 2 l of distilled water for 2 hours and then filtrated. The filtrate was decompressed using a rotary vacuum evaporator (Lab. Camp, Daejeon, Korea) and lyophilized in a programmable freezedryer (IlShin Lab, Daejeon, Korea). Total acquired lyophilized extracts were 34.93 g (yield 11%). Powders of extracts were stored in a desiccator to protect against light and moisture. It was well dissolved up to 100 mg/ml concentration levels and appeared to be a deep brown solution. The test article was single orally administered at a dosage volume of 20 ml/kg using distilled water as vehicle.
Grouping and dosing. The animals were distributed into 8 groups of 5 mice per group upon receipt. All 7 herbal components of DHU001 have been used as folk medicine and ingredients of medicinal food for long times without revealed toxicological data. The highest dosage level was selected as 2000 mg/kg according to the recommended by KFDA (2005 KFDA ( -60, 2005 and Organization for Economic Co-Operation and Development (OECD) (2001) guidelines, and the limited dosages, 1000, 500 and 250 mg/kg, were selected using common ratio 2. In addition, a vehicle control group was added. Animal was once orally dosed using a sonde attached to a syringe of 1ml after overnight fasting (about 18 hr, water was not restricted). Feed and water were restricted further for about 3 h.
Observation of clinical signs. All abnormal clinical signs were recorded before and after dosing at least twice a day based on the functional observational battery test (Irwin, 1968; Dourish, 1987) .
Body weight changes. Body weights were measured at the day of dosing (Day 0) immediately before treatment, 1, 2, 7, 13 and 14 days after dosing. In addition, to reduce the individual body weight differences of animals at initial dosing, body weigh gains during Day 0~Day 7, Day 7~Day 13 and Day 0~Day 13 were also calculated based on measured body weight at each day.
Necropsy. All unscheduled dead animals were grossly observed immediately after finding and all survived animals were subjected to terminal necropsy. Animals were asphyxiated by carbon dioxide and gross necropsy was performed in all animals at Day 14 after overnight fasting (about 18 h, water was not restricted).
Specific organs grossly observed: Lung, heart, kidney, spleen, testis, liver, pancreas, epididymis, popliteal lymph node, ovary, brain, and uterus.
Organ weight measurement. The absolute organ weight was measured and then relative organ weight (% of body weight) was calculated for the following organs of all experimental animals when sacrificed.
Measured organs: Lung, heart, kidney (left), spleen, testis (left), liver, pancreas (splenic lobes), epididymis (left), popliteal lymph node (left), ovary (left), brain, and uterus.
Histopathology. Principle organs listed below were sampled at terminal necropsy, and fixed in 10% NBF (neutral buffered formalin). After 18 h of fixation, paraffin embedding was conducted and 3~4 µm sections were prepared by routine histological methods. Representative sections of each specified organs were stained with Hematoxylin & Eosin for light microscopical examination.
Specific organs sampled: Lung, heart, kidney (left), spleen, testis (left), liver, pancreas (splenic lobes), epididymis (left), popliteal lymph node (left), ovary (left), brain, and uterus.
Statistical analyses. Multiple comparison tests for different dose groups were conducted. Variance homogeneity was examined using the Levene test. If the Levene test indicated no significant deviations from variance homogeneity, the obtained data were analyzed by one way ANOVA test followed by Tukey HSD test to determine which pairs of group comparison were significantly different. In case of significant deviations from variance homogeneity were observed at Levene test, a non-parametric comparison test, the Mann-Whitney U-Wilcoxon Rank Sum W test was conducted to determine the specific pairs of group comparison, which are significantly different. LD 50 and 95% confidence limits were calculated by Probit method. Statistical analyses were conducted using SPSS for Windows (Release 14.0K, SPSS Inc., USA) and a p-value of less than 0.05 was considered to be a significant difference. In addition, degree of clinical signs, gross and histopathological findings were subdivided into 3 degrees: 3+ Severe, 2+ moderate, 1+ slight.
RESULTS

Mortalities.
No unscheduled or DHU001-treatment related mortalities were detected in all dose levels tested in this study. At termination, all of animals (5/5; 100%) were survived in all dose levels tested including vehicle control.
Clinical signs. In this study, DHU001-treatment related abnormal clinical signs were not observed during observation periods regardless of male and female mice.
Changes on body weights and gains. No significant changes on body weight and gains were detected in all dosing groups tested compared to the vehicle control in all dose levels tested ( Fig. 1 and 2 , Table 2 ).
Changes on the organ weight. No significant changes on the absolute and relative organ weight of 12 principle organs were observed in all dosing groups tested compared to the vehicle control except for significant (p < 0.05) increase of absolute and relative weights of thymus in DHU001 1000 mg/kg-treated male group as compared with equal gender of vehicle control (Table 3 and 4).
Necropsy findings. No significant changes on the gross findings of 12 principle organs were observed in all dosing groups tested compared to that of vehicle control except for some accidental findings such as congestion spots of lung, atrophy of thymus, spleen atrophy or hypertrophy, atypical white foci of liver, hypertrophy of popliteal lymph nod and edematous changes of uterus. They were randomly detected throughout the whole experimental groups including each gender of vehicle controls, and most of these sporadic gross findings do not show any dose-dependent frequencies encounted (Table 5) .
Histopathological findings. No significant changes on the histopathological findings of 12 principle organs were observed in all dosing groups tested compared to that of vehicle control except for some sporadic accidental findings such as hypertrophy of lung alveolus wall as congestion, depletion of lymphoid cells or focal hemorrhages in the cortex of thymus, focal necrosis and inflammatory cell infiltration in liver and desquamation of the uterus mucosa. They were randomly detected throughout the whole experimental groups including each gender of vehicle controls, and most of these sporadic histopathological findings do not show any dose-dependent frequencies encounted (Table 6) .
DISCUSSION
In the present study, we investigated the acute toxicity of single oral dose with DHU001, a polyherbal formula to female and male mice as a part of the safety test. DHU001 were once orally administered to female and male ICR mice at dose levels of 2000, 1000, 500, 250 and 0 mg/kg according to the recommendation of KFDA Guidelines (2005) . The mortality, changes on body weight, clinical signs and gross observation were monitored during 14 days after treatment of DHU001, and organ weight and histopathology of 12 types of principle organs were also conducted.
As the results, we could not find any mortality, clinical signs, changes in the body weight and gross findings and some sporadic gross findings In addition, no significant changes on the organ weight and histopathology of 12 types of principle organs were detected in the present study except for dose independent sporadic accidental changes.
The body weight detected in this study was well corresponded to the body weight ranges of same aged normal mice (Plata and Murphy, 1972; Yamaguchi et al., 1983) in all tested groups including both male and female vehicle control, respectively. It means DHU001 did not induce any harmful changes on the body weights.
In KFDA Guidelines (2005) and OECD Guidelines (#423, 2001), the recommended highest dose of test materials were 2000 mg/kg or the maximum solubility, and they also recommended that in case of single dose toxicity in mice, the dosage volume were below 20 ml/kg in case of clear soluble materials but 10 ml/kg in suspensions. In the present study, the highest dose of DHU001 was selected as 2000 mg/kg because all 7 individual herbal components of DHU001 have been used as folk medicine and ingredients of medicinal food for long times and no revealed toxicological data was available, base on the recommendation of KFDA (2005 KFDA ( -60, 2005 and OECD Guidelines (#423, 2001) , and treated in a volume of 20 ml/kg using distilled water as vehicle because DHU001 were clearly dissolved upto 100 mg/ml, at least in the present study. Significant (p < 0.05) increases of absolute and relative thymic weights in DHU001 1000 mg/kg male mice were considered unrelated to DHU001 treatment because they did not show dose-dependency with no specific changes on the histopathological profiles of thymus, and the other organ weights measured in this study well corresponded to the normal mice organ weight ranges as previously (Plata and Murphy, 1972; Yamaguchi et al., 1983) .
Edematous changes in the uterus at gross findings and related desquamation of uterus mucosa at histopathological observation in the present study were also considered as a result of differences of physiological estrus cycles (Banks, 1986; Pineda, 1989 ) not DHU001 treatment relative changes. They were also detected in vehicle control. The atypical white foci detected in one mouse of male vehicle control and DHU001 250 mg/kg treated groups revealed as slight focal necrosis and inflammatory cell infiltrations at histopathological observations.
Congestion spots of lung, atrophy of thymus, spleen atrophy or hypertrophy and hypertrophy of popliteal lymph nod detected as gross findings, and hypertrophy of lung alveolus wall as congestion, depletion of lymphoid cells or focal hemorrhages in the cortex of thymus detected in histopathological findings were considered as accidental findings and they were not considered to be DHU001 treatment related abnormal gross or histopathological findings because they were restricted in some individual animals and most of them were also observed in male and female vehicle controls. In addition, most of them were rarely observed in normal mice (Lee et al., 2005 .
Recently Notified Guidelines by KFDA (2005 KFDA ( -60, 2005 ) and OECD Guidelines (#423, 2001) recommended that the highest oral dose of test materials was 2000 mg/kg. The LD 50 and ALD in mice after single oral dose of DHU001 were detected over 2000 mg/kg in both male and female in the present study.
The results obtained in this study suggest that LD 50 and approximate LD in mice after single oral dose of DHU001 were considered over 2000 mg/kg in both female and male mice, and is likely to be safe in humans.
